| 联合检测血清CEA、CA125、CA153在N0期肺腺癌中的临床意义 |
| |
| 引用本文： | 罗远芳,黄俊.联合检测血清CEA、CA125、CA153在N0期肺腺癌中的临床意义[J].医疗保健器具,2011,18(3). |
| |
| 作者姓名： | 罗远芳 黄俊 |
| |
| 作者单位： | 1. 广东省广州市红十字会医院,检验科,广东,广州,510220
2. 广州医学院第一附属医院,胸外科,广东,广州,510180 |
| |
| 摘 要： | 目的 探讨血清癌胚抗原(CEA)、糖类抗原125(CA125)及糖类抗原153(CA153)联合检测在淋巴结转移阴性的肺腺癌预后判断中的价值.方法 收集197例淋巴结转移阴性的肺腺癌患者血清,采用美国ABBOTrAxsymx型电化学发光仪对血清CEA、CA125、CA153进行检测,并作单因素及多因素生存分析,探讨三项标志物对预后的判断意义.结果 肿瘤标志物CEA、CA125、CA153检测阳性率分别为51.8%(102/197)、26.9%(53/197)和24.4%(48/197).三项标志物联合检查至少有l项标志1次阳性的百分率为61.9%(122/197).单因素生存分析发现CEA、CA125、CA153是影响本组患者生存的预后因素(P ＜0.05),比例风险Cox模型的多因素生存分析提示CEA、CA125、CA153均是影响本组患者生存的独立预后因素.结论 CEA、CA125、CA153三项标志在淋巴结阴性的肺腺癌患者中有较高的阳性率,三项标志联合检测的阳性率高于任一标志单独检测的阳性率,联合检测有助于提高肺癌诊断的准确性;其次,CEA、CA125、CA153可作为淋巴结阴性患者的预后判断指标.
|
| 关 键 词： | 糖类抗原 肺腺癌 联合检测 |
The Clinical Value of Serum CEA, CA125 and CA153 Detection in 197 Patients with pN0 Lung Adenocarcinoma |
| |
| LUO Yuanfang,HUANG Jun.The Clinical Value of Serum CEA, CA125 and CA153 Detection in 197 Patients with pN0 Lung Adenocarcinoma[J].Medicine Healthcare Apparatus,2011,18(3). |
| |
| Authors: | LUO Yuanfang HUANG Jun |
| |
| Institution: | LUO Yuanfang 1,HUANG Jun 2(1Department of Clinical Laboratory,Guangzhou Red Cross Hospital,Guangzhou 510220,China,2Department of Chest Surgery,the First Affiliated Hospital of Guangzhou Medical College,Guangzhou 510180,China) |
| |
| Abstract: | Objective To evaluate the clinical value of combined assay of serum carcinoembryonic antigen (CEA),carbohydrate antigen 125 (CA125) and earbohydrate antigen 153 (CAl53) in patients with pN0 lung adenocarcinoma.Methods We collected 197 pN0 lung adenocarcinoma patients' clinical information and the serum levels of CEA,CA125,CA153.Kaplan-Meier was used to calculate the overall survival time.Results The positive rate of CEA was 51.8% (102/197),CA125 was 26.9% (53/197),CA153 was 24.4% (48/197).The positive rate ... |
| |
| Keywords: | Carbohydrate antigen Lung adenocarcinoma Combined assay |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
